Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

about

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q48335342

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@en

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@nl

type

Item

label

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@en

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@nl

prefLabel

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@en

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.

@nl

P1476

Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma

@en

P2093

Haige Ye

http://www.w3.org/2001/XMLSchema#string

Hun J Lee

http://www.w3.org/2001/XMLSchema#string

Jorge Romaguera

http://www.w3.org/2001/XMLSchema#string

Krystle Nomie

http://www.w3.org/2001/XMLSchema#string

Michael L Wang

http://www.w3.org/2001/XMLSchema#string

Onyeka Oriabure

http://www.w3.org/2001/XMLSchema#string

Wendy Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Postibrutinib outcomes in patients with mantle cell lymphoma.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P304

561-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14669

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P50

Samer A Srour

P577

2017-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28369820

http://www.w3.org/2001/XMLSchema#string